2026-06-17T08:40:57Z https://icatplus.esrf.fr/oaipmh/request

oai:icatplus.esrf.fr:inv/1452724880 2025-05-23T19:29:12.839Z

4.2 EI 10.15151/ESRF-ES-1452724880 Ahmed KHAMASSI Ahmed Khamassi 0000-0002-0835-7683 Matthew BOWLER Matthew Bowler 0000-0003-0465-3351 Gerlind SULZENBACHER Gerlind Sulzenbacher 0000-0003-4844-2820 Gerlind SULZENBACHER Gerlind Sulzenbacher 0000-0003-4844-2820 Sarah BARELIER Sarah Barelier 0000-0002-1084-6312 Thomas MILLER Thomas Miller 0000-0001-8645-2785 Stephane BETZI Stephane Betzi 0000-0001-5935-5058 Example Institute 2027 Data from large facility measurement 2024-03-02T08:30:00Z/2024-03-02T16:00:00Z 2024-03-02T16:00:00Z I CC-BY-4.0 The BAG groups 11 teams from 6 Marseille laboratories. It has lately been reorganized, with 2 PIs changing affiliation, and 2 laboratories revisiting internal organisation, but mutual understanding amongst all PIs provides a solid base for efficient organization of the BAG. Research revolves around infection, health and biotechnology. For the next beam time allocation period we could make efficient use of 10 MX and 2 SAXS shifts. This amount of beam time reflects what we had asked for in previous rounds. 3 teams combine structural biology with medicinal chemistry and beam time at MASSIF for large ligand-screening campaigns will mostly suit their purpose. Access to beamlines with tuneable energy will be instrumental for projects requiring experimental phasing. One team uses exclusively Bio-SAXS and allocation of one shift/session would be welcomed. Remote access for MX sessions has become very popular whereas scientists prefer to be on-site for Bio-SAXS experiments.